• Dr. Kan Gong: Research Progressin ASCO-GU 2023 Kidney Cancer

    The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of kidney cancer diagnosis, a novel molecular imaging agent, 89Zr-DFO-girentuximab, has been shown to accurately diagnose clear cell renal cell carcinoma (ccRCC). In the first-line treatment area, the CheckMate 9ER study…

  • Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis…

  • Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

    Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into…

  • Urinary Tumor DNA for MRD Detection in NMIBC rTURBT

    The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off in San Francisco on February 16, 2023. On the second day of the conference, during a special session on urothelial carcinoma, Professor Kyle M. Rose from the H. Lee Moffitt Cancer Center presented a prospective study on using cfDNA/utDNA for MRD detection…

  • Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients, International Clinical Trial Designs Should Consider This Factor

    Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao’s team suggests that among patients receiving different treatment regimens, Asian males have superior overall survival (OS) and cancer-specific survival…

  • Comprehensive Research from West China Hospital of Sichuan University

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) was held in San Francisco, USA, from February 16th to 18th, 2023. Dr. Qiang Wei and Dr. Hao Zeng’s team had multiple findings selected for academic exchange at this ASCO-GU symposium. Their work addressed prostate cancer, urinary tract carcinoma, and kidney cancer, covering…

  • Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

    The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass…

  • Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including…